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Abstract The deposition of budesonide at fast (60 lmin71) and slow (30 lmin71) inspiratory £ow rates from Air-
maxTM, a newmulti-dose dry powder inhaler, was compared with that fromTurbuhaler1 and a standard pressurized
metered dose inhaler (pMDI).Twelve patientswithmild tomoderate asthma tookpart in a ¢ve-wayrandomized cross-
over study, and inhaled a single nominal dose of 200 mg budesonide, labelledwith 99mTc, on each study day. Deposition
was determined bygamma scintigraphy.
At the fast £owrate,AirmaxTMandTurbuhaler1deposited 25?8+6?5% (mean+SD) and 29?8+6?9%, respectively, of
the delivered dose in the whole lung (P= 0?080). At the slow £ow rate, AirmaxTM deposited 28?3+5?6%,Turbuhaler1
22?7+5?6% and pMDI12?1+3?4%.Using data on emitted doses determined in vitro, it was estimated that AirmaxTM
deposited 53?1+13?3 mg and 43?6+8?6 mg budesonide in the lungs at 60 lmin71 and 30 lmin71 respectively, whilst
Turbuhaler1deposited 48?3+11?2 mgat 60 lmin71and 24?2+ 6?0 mgat 30 lmin71.
Inconclusion, lungdepositionof budesonide fromAirmaxTMwascomparabletothatof Turbuhaler1at ahigh £owrate
butwasmarkedly superior toTurbuhaler1 andpMDI at a lower £owrate.UnlikeTurbuhaler1,AirmaxTM performswith
relative £ow^rate independence.c 2002 Elsevier Science Ltd.
doi:10.1053/rmed.2001.1171, available online athttp://www.idealibrary.comon
Keywords Turbuhaler1; gamma scintigraphy; asthma; clinical study; MDI; planar imaging.INTRODUCTION
Ine⁄cient inhaler use has long been recognized as a ma-
jor problem formanypatientsusingpressurizedmetered
dose inhalers (pMDIs) who have di⁄culty in co-ordinat-
ing actuation of the device with inhalation (1). Such pro-
blems, together with the phasing out of the
chloro£uorocarbon propellants used in the original for-
mulations of MDIs, have resulted in the development of
dry powder inhalers (DPIs). Patients generally ¢nd DPIs
easier to use than pMDIs since they are breath-actuated
anddo notrequire co-ordination of actuation and inhala-
tion. Furthermore DPI’s operate without the need for
potentially environmentally damaging propellants. How-
ever in vivo lung deposition can be in£uenced by the pa-
tient’s inspiratory £ow rate, and this may be particularly
relevant for patients with severe asthma, the elderly and
young children (2). Pulmicort Turbuhaler1 (AstraZene-
ca, Lund, Sweden) is a multi-dose DPI that has been
widelyused for the deliveryofbudesonidepowder.How-Received19 May 2001and accepted in revised form19 June 2001.
Correspondence should be addressed to: Michae« l GL Hertog, PhD,
Medical A¡airs Europe,Yamanouchi Europe, Elisabethhof19,NL-2350
ACLeiderdorp,The Netherlands.Fax: +315455739; E-mail:
mhertog.nl@yamanouchi-eu.comever, it is well documented that the amount of drug de-
livered from theTurbuhaler1 varies greatly fromdose to
dose, and that particularly the ¢ne particle dose is re-
duced signi¢cantly whenusedwith a lowinspiratory £ow
rate (3,4).
AirmaxTM is a trademark of Yamanouchi Europe BV
(Leiderdorp, The Netherlands) for a novel multi-dose
(200 doses) DPI, which utilizes proprietary technology
known as the X-ACTTM system (Fig. 1). This active-me-
tering, cyclone-separator technology was designed to
provide accurate and consistentdosing to thepatient lar-
gely independent of inspiratory e¡ort. Unlike other de-
vices which rely on gravity, X-ACTTM uses controlled air
pressure from an internal pump to exactly meter the
dose. The inhaler is simply operated by opening the
mouthpiece cap, inhaling and closing again. Closing of
the cap triggers the precise dose counter.When the pa-
tient inhales, the dose is transported into the cyclone se-
parator, which separates the drug from its lactose
carrier and produces a high ¢ne particle dose. Gravi-
metric studies and studies with multi-stage liquid impin-
gers have shown typical relative standard deviations of
dose consistency of 5%, emitted doses between 90^
105% of label claim and ¢ne particle fractions between
49^59% (5,6).
FIG. 1. Diagram of AirmaxTM inhaler with stage 1 (active me-
tering) and 2 (cyclone separator).
390 RESPIRATORYMEDICINEThe aim of the present study was to con¢rm the in vi-
tro results using a validated gamma scintigraphic techni-
que (7^9), and to compare the delivery of budesonide
from AirmaxTM with that fromTurbuhaler1 at di¡erent
£ow rates and with that from a pMDI. In order to make
the data as clinicallyrelevant as possible, resultswere ex-
pressed both as percentage of delivered dose and as
mass of budesonide deposited in the lungs.
METHODS
STUDYPOPULATION
Sixteen volunteers aged 18^55 years with a diagnosis of
asthma at least 6 months prior to study entry were
screened, of whom 13 were subsequently entered into
the study. All patients hadwithin theprevious 2 years de-
monstrated a forced expiratory volume in1sec (FEV1) at
least 60% predicted for their height andgender, and a re-
versibility of at least10% in FEV1 following inhalation of a
standard 200mg dose of salbutamol from a pMDI. Pa-
tients were excluded if they had upper or lower respira-
tory tract infection within the previous 2 weeks. All
patients gave written informed consent to their partici-
pation after full explanation of the nature of the study,
which was approved by the Quorn Research Review
Committee, Leicestershire,UK, andperformed in accor-
dancewith the Declaration of Helsinki.STUDYDESIGN
The study was carried out according to a randomized,
open label, cross-over design during ¢ve study periods,
each separatedby aminimumperiodof 44h.During each
study period patients inhaled 26100mg of salbutamol
followed15^30min later by a single (200mg) dose of bu-
desonide labelled with up to 10MBq 99mTc administered
either from AirmaxTM orTurbuhaler1 at targeted peak
inspiratory £ow rates (PIFR) of 30 lmin71 or 60 lmin71,
and from a standard pMDI (Pulmicort1) at a targeted
PIFR of 30 lmin71. Subjects were instructed to inhale
deeply and to follow inhalation with a10 sec breath-hold
and exhalation via a low resistance ¢lter. Each subject
practiced the inhalation manoeuvre with a placebo de-
vice until the inhalation technique had beenmastered. A
Vitalograph MDI^Compact Spirometer (Vitalograph
Ltd, Maids Moreton, Buckinghamshire, U.K.) connected
in series with the inhaler devices recorded peak inspira-
tory £ow rates, inhaled volumes and breath holding
pauses. AMicroloop spirometer (Micro Medical, Roche-
ster, U.K.) was used to record FEV1 before dosing and
then 60 min post-dosing.
RADIOLABELLINGOFBUDESONIDE
Budesonide from the Turbuhaler1 was radiolabelled as
described previously (10). Brie£y, the radiolabel (99mTc)
was extracted from saline into methyl ethylketone, and
after removal of the solvent by evaporation, was redis-
solved in water andmixedwith budesonide powder.The
water was then removed by freeze-drying and the radi-
olabelled powder transferred to an empty Turbuhaler.
For AirmaxTM, a similarmethodwas used to obtain radi-
olabelled budesonide powder, 100mg of which was
blended with lactose (2050mg) in a Turbula mixer
(42 rpm) for 30min.EachAirmaxTMdevicewas ¢lledwith
730mg of this blend.
Themethod for the pMDI was as follows: the radiola-
bel (99mTc) was extracted into methyl ethylketone and
transferred to an empty pMDI canister. After removal
of the solvent the contents of a full canister previously
cooled in liquid nitrogen were added to the residue and
a newmetering valve was crimped in place.The canister
was sonicated for10min in order to ensure even disper-
sion of the radiolabel throughout the formulation.
In order to show that the radiolabel was a valid mar-
ker for budesonide, the size distributions of drug before
labelling, of drug after labelling and of 99mTc radiolabel
were compared. A High Precision Multistage Liquid Im-
pinger (HPMLI, Copley Instruments, Nottingham, U.K.)
was used for the two DPIs, and an Andersen Cascade
Impactor (ACI, Copley Instruments) for the pMDI. The
test method was based on pharmacopeial standards i.e.
testing at a pressure drop of 4kPa across the device for
theDPIs and a £owrate of 28?3 lmin71for thepMDI.The
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products were not changed signi¢cantly by the radiola-
belling procedure, and that the radiolabel and drug
matched one another across the full range of particle
size bands.
GAMMASCINTIGRAPHY
Immediately following administration of the radiola-
belled formulation, posterior and anterior views of the
chest and a right lateral viewof the oropharynx were re-
cordedusing a gamma camera (General Electric Maxica-
mera, Milwaukee, WI, U.S.A.) connected to a Park
Medical computer system (Farnborough, U.K.). On one
study day, unless available from a previous study within
the previous 2 years, a posterior lung ventilation scan
was performed on each patient using the radioactive in-
ert gas 81mKr in order to de¢ne the edges of the lung
¢elds.The lungs were subdivided into central, intermedi-
ate and peripheral regions of interest as previously de-
scribed (11), thus enabling the percentage of the dose in
each lung zone to be determined and the peripheral lung
zone /central lung zone deposition ratio to be calculated.
The counts obtained within these regions were cor-
rected for background radioactivity, radioactive decay,
acquisition time and for tissue attenuation of gammarays
(12). In regionswhereboth anterior andposterior images
were recorded, the geometric mean of counts in both
images was calculated prior to correction for tissue at-
tenuation. Deposition in the oropharynx included activ-
ity adhering to themouth andoropharynx togetherwith
any swallowed activity detected in the oesophagus, sto-
mach and intestine and activities deposited on the
mouthpiece of the exhalation ¢lter. Since the mouth-
piece of the AirmaxTM cannot be separated from the
body of the device, it was not possible to quantify de-
position on the AirmaxTMmouthpiece.Data for all three
devices were expressed as percentage of delivered
(emitted) dose from the sum of corrected total body
counts and those on the exhaled air ¢lter.
The actual masses of budesonide deposited in the
lungs were calculated by using actual delivered masses
at the relevant £ow rates determined by in vitro analysis.
Using an HPMLI delivered doses at the £ow rates of
60 lmin71 and 30 lmin71 for each DPI (n=3) were ¢rst
determined. Mean dose delivered by the pMDI was as-
sumed to be equal to the nominal dose of 200mg. Lung
deposition values expressed asmass of budesonidewere
calculated as (% delivered dose in lungs)6 (mean mea-
sured delivered dose) /100.
STATISTICALANALYSIS
The study was designed to detect di¡erences between
the patterns of lung deposition from di¡erent devices atthe two £ow rates. Since clinically relevant di¡erences
were unknown, an arbitrary 4% di¡erence in total lung
deposition was selected for power calculations. Based
on previous studies which had demonstrated whole lung
deposition of a range of inhalers averaging 15% of the
dose, with a standard deviation of 3% of the dose, it was
calculated that10 evaluable patients would be needed to
detect a di¡erence of 4% with a=0?05 and a power of
80%.
Three contrasts were de¢ned and were statistically
analysed using analysis of variance (ANOVA) model,
including terms for patient, treatment and sequence.
These contrasts were: AirmaxTM at 60 lmin71 vs.
Turbuhaler1 at 60 lmin71, AirmaxTM at 60 lmin71 vs.
30 lmin71 and Turbuhaler1 at 60 lmin71 vs. 30 lmin71.
Because the least square means % deposition and
mass deposited calculated from ANOVA did not
di¡er from the actual crude means, only the crude
means and their standard deviation are reported
here. All reported P-values are based on this ANOVA,
and a P-value of 50?05 was considered statistically
signi¢cant.
RESULTS
RADIOLABELLINGVALIDATION
The results of the radiolabelling validation experiments
are shown in Table 1. For all devices there was a good
match between the ¢ne particle fractions (FPFs) of deliv-
ered dose for the drug before labelling, the drug after la-
belling and the radiolabel itself.Hence the radiolabelwas
considered to be a validmarker for the drug for all three
products. The radiolabel FPFs of the inhalers used on
study days were determined before dosing, and were
shown to be within the range of values determined in
the prestudy validation testing.
PATIENTS
Demographic variables of the patients are shown in
Table 2. Of the 13 patients that entered the study, 12
completed the 60 lmin71armswith theDPIs and11 com-
pleted the 30 lmin71arms.
Inhalationmanoeuvres and lung function
Table 3 displays details of the inhalation manoeuvres for
each device and of lung function pre- and post-dosing.
Mean PIFR was above target for AirmaxTM and pMDI,
and close to target forTurbuhaler1.Meanbreath-holding
times and inhaled volumes were comparable for all ¢ve
treatment regimens.
TABLE 1. Mean (SD) Results ofthe radiolabelling validation assessment
Flowrate Fine particle fractions (% delivered dose)
lmin71 Drugbefore
labelling (%)
Drugafter
labelling
Radiolabel
(%)
AirmaxTM (n = 5) 70 42?7+1?9 40?6+4?2 43?4+3?2
Turbuhaler1 (n= 5) 60 57?6+1?3 57?7+3?4 56?0+6?3
pMDI (n= 5) 28?3 35?9+3?1 34?6+1?8 40?1+6?1
TABLE 2. Meandemographic and baseline characteristics of randomizedpatients
Gender Male
Female
6
7
Age (years) Mean (range) 34?7 (20^52)
Height (cm) Mean (range) 172?3 (154^186)
Weight (kg) Mean (range) 73?4 (59^105)
Race Caucasian 12 (92?3%)
Asian 1 (7?7%)
Baseline FEV1 (l) Mean (range) 3?05 (2?20^3?94)
% Predicted FEV1at baseline Mean (range) 86?7 (67?1^104?5)
TABLE 3. Mean average and peak inspiratory £ow rates, breath-holding times, inhaled volumes and FEV1 pre- and 60min
post-dosing
AirmaxTM Turbuhaler1 pmdi
Targeted PIFR l/min71 60 30 60 30 30
n 12 11 12 11 11
Peak inspiratory £ow (lmin71) 71?64 37?45 59?75 31?60 38?91
(SD) (11?81) (6?33) (13?80) (3?24) (13?76)
Inhaledvolume (l) 2?49 2?73 2?99 3?04 2?60
(SD) (0?89) (0?77) (0?99) (1?03) (1?0)
Breath-holding time (sec) 10?0 10?4 10?0 9?5 10?6
(SD) (1?0) (1?8) (1?5) (0?9) (1?2)
Pre-dose FEV1 (l) 3?00 2?89 2?98 2?80 2?98
(SD) (0?57) (0?59) (0?51) (0?41) (0?52)
60minpost-dose FEV1 (l) 3?24 3?18 3?25 3?25 3?28
(SD) (0?52) (0?52) (0?52) (0?52) (0?56)
392 RESPIRATORYMEDICINEDEPOSITIONDATA
Scintigraphic images showing deposition patterns for
each of the ¢ve dosing regimens are shown in Fig. 2.The
mean (+ SD) whole lung deposition expressed as percen-
tage of delivered dosewas 25?8+6?5% and 29?8+6?9%
for AirmaxTM and Turbuhaler1, respectively, at the fast
inspiratory £ow rate (60 lmin71). This di¡erence was
not statistically signi¢cant (P=0?080). At 30 lmin71, Air-
maxTM deposited 28?3+5?6% and Turbuhaler122?7+5?6% of the delivered dose in the whole lung.The
small increase in deposition for AirmaxTM at the lower
£ow rate was not statistically signi¢cant (P=0?208),
whereas the decrease in performance at lower £owrate
for Turbuhaler1 was signi¢cant (P=0?003).Whole lung
deposition was lowest for the pMDI (12?1+3?4%), while
oropharyngeal deposition was highest (86?8+ 3?8%)
with thepMDI.Regional depositionpatternswere similar
for all treatments with the peripheral zone being the
(a) (b)
(c) (d)
(e)
FIG. 2. Scintigraphic imagesobtainedusingAirmaxTMat (a) 60 lmin71 (b) 30 lmin71;Turbuhaler1at (c) 60 lmin71 (d) 30 lmin71and
(e) a pMDI at 30 lmin71.
LUNGDEPOSITIONOFBUDESONIDEFROMAIRMAXTM 393major deposition site (Table 4).Theperipheral lung zone/
central lung zone deposition ratios tended to be higher
for AirmaxTM than forTurbuhaler1 but these di¡erences
were small.
Using HPMLI testing at 60 lmin71, we found that
AirmaxTM delivered 206+4mg budesonide andTurbuhaler1 162+33mg budesonide (nominal doses
200mg for both products). At a £ow rate of 30 lmin71
delivered dose dropped to 154+ 27mg for AirmaxTM
and to107+39mg forTurbuhaler1.Using themean deliv-
ered dose values we estimated that in patients inhaling
at a target £ow of 60 lmin71 AirmaxTM deposited
TABLE 4. Summaryof deposition data based on delivered dose of budesonide by inhaler and inspiratory £ow
AirmaxTM Turbuhaler1 pMDI
Targeted PIFR lmin71 60 30 60 30 30
n 12 11 12 11 11
Whole lung (%) 25?8 28?3 29?8 22?7 12?1
(SD) (6?5) (5?6) (6?9) (5?6) (3?4)
Central lung (%) 6?5 7?4 8?5 6?5 3?0
(SD) (1?7) (2?1) (2?1) (2?5) (0?7)
Intermediate lung (%) 8?6 9?6 10?1 7?9 3?9
(SD) (2?0) (2?4) (2?5) (2?3) (0?9)
Peripherallung (%) 10?7 11?4 11?2 8?3 5?2
(SD) (3?3) (2?0) (3?0) (4?1) (2?0)
Oropharynx (%) 73?6 71?4 69?1 76?0 86?8
(SD) (6?7) (5?5) (7?0) (6?2) (3?8)
Exhalation ¢lter (%) 0?3 0?6 1?3 1?1 1?1
(SD) (0?2) (0?4) (3?0) (0?8) (0?7)
Peripheral/centralratio 1?7 1?7 1?4 1?5 1?8
(SD) (0?4) (0?5) (0?3) (0?8) (0?6)
FIG. 3. Mass of budesonide (in mg) depositedbyinhaler and inspiratory £ow.
394 RESPIRATORYMEDICINE53?1+13?3mg and Turbuhaler 48?3+11?2mg in the
lungs (Fig. 3). As with percentage deposition data, the
estimated mass of budesonide deposited in the whole
lungs with AirmaxTM did not di¡er signi¢cantly from
the mass deposited by Turbuhaler1 at 60 lmin71
(P=0?224). The estimated mass deposited in the lungsdropped to 43.6+ 8.6mg for AirmaxTM at 30 lmin71
(P=0?032 compared to 60 lmin71).Turbuhaler1 depos-
ited in the lungs at 30 lmin71 only about half of the
amount compared to 60 lmin71 (24?2+ 6?0mg,
P50?001) and this amountwas similar to that deposited
by pMDI (24?1+6?7mg).
LUNGDEPOSITIONOFBUDESONIDEFROMAIRMAXTM 395Safety
A total of 11mild to moderate adverse events were re-
ported by nine patients, of whom ¢ve reported adverse
eventsbefore the ¢rst treatmentperiod. Adverse events
included headache, rhinitis and conjunctivitis. None of
thesewere considered toberelated to the studymedica-
tion or procedures. There were no serious adverse
events. There was no evidence of bronchoconstriction
for any of the study regimens.
DISCUSSION
The present study showed that the novel multi-dose
dry powder inhaler, AirmaxTM, deposited a mean 26%
of the delivered dose (mean 53mg budesonide) in the
lungs at the fast £ow rate of 60 lmin71. This amount
is similar to that delivered by Turbuhaler1 at this
£ow rate. At low inhaled £ow rate (30 lmin71) the per-
formance of AirmaxTM remained virtually unchan-
ged, whereas Turbuhaler1 delivered signi¢cantly less
budesonide. Both dry powder inhalers were superior
to pMDI when used at high inspiratory £ow rates.
The regional lung distribution patterns were broadly
similar between the di¡erent inhalers and £ow rates
investigated.
The data obtained in the present study are consistent
with those obtained in previous studies with Turbuha-
ler1 and pMDIs. At a peak inspiratory £ow rate (PIFR)
of 60 lmin71, lung deposition from the Turbuhaler1
averages between 14% and 32% of the metered dose
(13^17). A halving of PIFR to 30 lmin71 has been shown
previously to approximately halve lung deposition (16),
while lung deposition from a budesonide pMDI has been
shown to be approximately half of that from aTurbuha-
ler1 (13,14), whenbothTurbuhaler1 andpMDIwereused
optimally.
In the present study therewas a closematch between
actual PIFR and target values forTurbuhaler1, but with
AirmaxTM andwith thepMDI the PIFR tended to behigh-
er than target.This couldhavebiased theresults towards
a better performance for AirmaxTM.However, the di¡er-
ence betweenTurbuhaler1 (PIFR 59?8 lmin71) and Air-
maxTM (71?6 min71) closely resembled the di¡erence
(i.e. about 70 l/minvs. 60 lmin71for AirmaxTM andTurbu-
haler1, respectively) observed in in vitro studies (Table1)
whenboth inhalers are tested at a pressure drop of 4kPa
as requiredby Pharmacopoeial guidelines (18).This di¡er-
ence is causedby thehigher internalresistance of theTur-
buhaler1. This suggests that the inspiratory e¡ort
applied by the patients in this trial was similar for both
AirmaxTM and Turbuhaler1 and hence the comparison
is justi¢ed.
The use of gamma scintigraphy, as other imaging tech-
niques, does not allow direct quanti¢cation of the mass
of drug deposited. In order to understand as fully as pos-sible the clinical relevance of our ¢ndings, we estimated
lung deposition expressed not only as percentage of de-
livered dose, but also as mass of budesonide deposited
into the lungs, based on separate laboratory measure-
ments of delivered (emitted) dose. In our in vitro analysis
we showed that AirmaxTM delivered 103% of the label
claim at 60 lmin71 and 77% at 30 lmin71, hence there
was a drop in estimated mean mass deposited in the
lungs of about10mg when the £ow rate through the Air-
max was halved. For Turbuhaler1 this drop in perfor-
mance was accentuated as the in vitro method showed
that at 60 lmin71 typically only 80% of the label
claim was emitted and at 30 lmin71 this dropped to
54% of the label claim.These data were consistent with
those reportedbyother investigators (15,16). As a conse-
quence partly of reduced percentage deposition, and
partly of reduceddelivered dose, themass of budesonide
deposited in the lungs was halvedwhen the inhaled £ow
rate through the Turbuhaler1 was reduced from
60 lmin71 to 30 lmin71. Lung deposition of budesonide
from Turbuhaler1 at 30 lmin71 was similar at around
24mg to lung deposition achieved by the pMDI at this
£ow rate.
There have been few studies to quantify the mass of
drug deposited into the lungs through imaging techni-
ques, and expressing the results in this way may give a
better correlation with clinical ¢ndings. Hence the re-
sults of lung deposition studies may be considered as a
‘bridge’ between the in vitro testing programme and clin-
ical trials carried out to assess the e⁄cacy of a novel
product in man (19). The clinical response to inhaled
anti-asthma drugs may depend not only upon the total
amount of drug deposited in the lungs, but also upon
the regional deposition pattern within the airways (20).
This was expressed in the present study as the
peripheral/central (P/C) ratio which has been shown
to correlatewith the relative amounts of drug deposited
in the tracheobronchial and alveolated airways of the
lungs (21). The similar P/C ratios for AirmaxTM and
Turbuhaler1 in this study suggest that both devices frac-
tionate the dose between the two major anatomical
regions of the lungs in a broadly similar manner. The
P/C ratios in this study weremore typical of those often
seen in healthy subjects, despite this being a patient
study. This could be a result of the predose administra-
tion of salbutamol, whichwas done in order to minimise
day-to-day variation in lung function in this cross-over
study.
We conclude that lung deposition of budesonide
from AirmaxTM and Turbuhaler1 are similar when
used by patients at ‘fast’ inspiratory £ows of 60 lmin71.
However, lung deposition from AirmaxTM at low £ow
rates is markedly superior to both Turbuhaler1 and
pMDI.UnlikeTurbuhaler1, AirmaxTMDPI performs rela-
tively independently of £ow rate and hence inspiratory
e¡ort.
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